TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Deep Dive Randomized Control Trial
Brief Summary: Compare two care management support program models on medical costs and utilization.


Options:
A: Inclusion Criteria:

* All employees, dependents and retirees in one of seven large employer groups, including a state university system, a state employee group, two manufacturing companies, a natural resource extraction company, a public educational service agency, and a nonprofit multiple employer association for independent colleges were eligible for inclusion.

Exclusion Criteria:

* no financial information was available from their facility and professional claims;
* they were in an employer sub-group ineligible for care support services;
* they asked not be to contacted or were deceased;
* gender information was missing from their eligibility files;
* their claims data from the year prior to the start of the study indicated diagnoses of HIV, AIDS, end-stage renal disease (ESRD), organ transplants, or necrotizing fasciitis (intended to improve the likelihood of a balanced distribution of costs and conditions); OR
* they were in an employer sub-group with less than four months of enrollment prior to the study start date (resulting in too little information for stratification).
B: * Have a diagnosis of type 2 diabetes mellitus of any duration; c-peptide test not required
* Use 1 or 2 oral hypoglycemic agents; not using insulin therapy
* Are not pregnant
* Have stable but inadequate glycemic control: both A1C at the time of eligibility and previous A1c within 6 months between 7-9.5%
* Recognize their primary care provider as their main diabetes care provider
* Do not have major barriers (i.e., severe hearing impairment, dementia, cannot communicate in English) to participate in shared decision-making (per provider?s assessment)
* Have no plans to relocate out of town in the next 6 months
* Enrolment is open to males and females of diverse racial backgrounds
C: Inclusion Criteria:

* Female age \< 39 years
* In first cycle minimum of two embryos available for transfer

Exclusion Criteria:

* Medical necessity for single embryo transfer
D: Inclusion Criteria:

* presenting for routine medical care with regular medical provider
* able to understand, speak, and read English

Exclusion Criteria:

* prior history of cardiovascular disease
* history of serious medical illness that would limit candidacy for screening
* previous participation in intensive risk modification as part of diabetes study in our clinic
* no cholesterol measurement in the last 3 years, limiting ability to provide up-to-date risk estimate

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Deep Dive Randomized Control Trial
Brief Summary: Compare two care management support program models on medical costs and utilization.


Options:
A: Inclusion Criteria:

* Diabetes with most recent HbA1c 8 or above in past 6 months.

Exclusion Criteria:

* Dementia,
* Life expectancy less than 6 months,
* Inability to speak English or Spanish.
B: Inclusion Criteria:

* All employees, dependents and retirees in one of seven large employer groups, including a state university system, a state employee group, two manufacturing companies, a natural resource extraction company, a public educational service agency, and a nonprofit multiple employer association for independent colleges were eligible for inclusion.

Exclusion Criteria:

* no financial information was available from their facility and professional claims;
* they were in an employer sub-group ineligible for care support services;
* they asked not be to contacted or were deceased;
* gender information was missing from their eligibility files;
* their claims data from the year prior to the start of the study indicated diagnoses of HIV, AIDS, end-stage renal disease (ESRD), organ transplants, or necrotizing fasciitis (intended to improve the likelihood of a balanced distribution of costs and conditions); OR
* they were in an employer sub-group with less than four months of enrollment prior to the study start date (resulting in too little information for stratification).
C: Inclusion Criteria:

* Diagnosis of diabetes and/or heart disease
* Poor disease control (defined as an HbA1c level of at least 8.5%, blood pressure greater than 140/90 mm Hg, LDL cholesterol greater than 130 mg/dL)
* Diagnosis of major depressive disorder

Exclusion Criteria:

* History of psychosis
* At high risk for suicide
* Cognitive impairment
* Current alcohol or substance abuse disorder
* Does not own a telephone
* Currently seeking psychiatric care
* Pregnant or breastfeeding
* Currently enrolled in a Group Health Cooperative disease management program
* Terminal illness
* Plans to leave Group Health Cooperative in less than a year
* Does not speak English
D: Inclusion Criteria:

* Diagnosis of type 2 diabetes (medication and HbA1c\>7% and no cardiovascular disease), coronary artery disease (history of myocardial infarction or revascularisation) or heart failure (NYHA II-III and admitted in a hospital for the condition within 2 years)
* Aged 45 years or older
* Resident in the Päijät-Häme health care district

Exclusion Criteria:

* Classified as ineligible by primary care physician
* Unable to co-operate or participate in health coaching
* Major elective surgery planned within 6 months
* History of major surgery within past 2 years
* Life expectancy \<1 year
* Pregnancy

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Impact of the Pharmaceutical Care Program for Pharmacological Treatment of Depression in Primary Care on the Compliance to Antidepressants and Patient Wellbeing
Brief Summary: The purpose of this study is to evaluate the impact of pharmaceutical services among patients starting a treatment with antidepressants for a diagnosis of depression. The hypothesis of the study is that pharmacist intervention can improve compliance to antidepressants and patient wellbeing.


Options:
A: Inclusion Criteria:

* Clinically Significant Depression

Exclusion Criteria:

* Sub-threshold Depression,
* Non-english speaking,
* Patients not having telephone access,
* Bereaved,
* Suicidal,
* Currently being treated by a mental health specialist,
* Bipolar disorder,
* Psychotic disorders,
* Drug or alcohol dependence,
* Cognitively impaired,
* Terminal illness,
* Having a court appointed guardian, or
* Pregnant (if applicable)
B: Inclusion Criteria:

* confirmed untreated infection (positive HCV RNA test)
* current PHQ-9 score of 10 or more
* current treatment in the CHC clinic

Exclusion Criteria:

* non-Veterans
* patients who do not have access to a telephone
* patients with current suicidal ideation
* patients with significant cognitive impairment as indicated by a score \> 10 on the Blessed Orientation Memory and Concentration Test
* patients with a chart diagnosis of schizophrenia
* patients with a chart diagnosis of bipolar disorder who have been hospitalized for a mental health condition within the last 12 months
C: Inclusion Criteria:

* Clinical diagnosis for depression from a general practitioner
* Beginning a pharmacological antidepressant treatment
* Going to one of the participant community pharmacies

Exclusion Criteria:

* Used antidepressant medication in the past 2 months
* Had an appointment with an specialist in mental disorders in the past 2 months
* History of psychotic or bipolar episodes
* History of drug abuse or dependency
* Cognitive impairment that not allows assessment
D: Inclusion Criteria:

PHQ9 Score \> or = to 12

Exclusion Criteria:

A diagnosis of schizophrenia, current suicide ideation, recent bereavement, or receiving specialty mental health treatment

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomised Controlled Trial Investigating a Mobile Phone Self-monitoring Tool (Mobiletype) to Increase Emotional Self-awareness and Reduce Depressive Symptoms in Young People.
Brief Summary: The mobiletype program is a mental health assessment and monitoring tool that runs on mobile phones.

The program assesses the general mental health of young people in real-time and transmits this data to a website to be reviewed by their general practitioner (GP) in consultation with their patient. The website consists of individualised feedback reports for each participant, and graphical displays of the monitoring data. The primary aims of the current project are to examine: (1) whether the process of self-monitoring via the mobiletype program increases young people's awareness of their mood and reduces depressive symptoms and (2) whether emotional self-awareness mediates the relationship between self-monitoring and depressive symptoms.


Options:
A: Inclusion Criteria:

* 18 years of age or older at time of consent, may be men or women.
* Capable of giving informed consent
* Have a cellular phone capable of receiving text messages.
* Able to adhere to the study visit schedule and other protocol requirements.

Exclusion Criteria:

* Non-English speaking individuals
B: Eligible clinician participants (Inclusion):

* Nurses, physicians, or physician assistants
* Perform consults/exams in clinics that have implemented routine use of the ESRA-C 2 screening tool as a standard of care

Eligible patient participants (Inclusion):

* 18 years of age or older
* Diagnosis of malignant disease
* Plan to have treatment in a study clinic
* Speak and read English at a 6th grade level or higher
C: Inclusion Criteria:

* Aged 14 - 24 years of age
* Proficient English
* Patients must be deemed to have an emotional/mental health concern by their GP or be screened to have at least a mild mental health problem (a score of 16 or above) on the K10 Symptom Scale

Exclusion Criteria:

* Severe psychiatric or medical condition that prevents the person from complying with either the requirements of informed consent or the study protocol.
* Young people referred to a mental health specialist by their GP will be excluded only if they obtain a specialist appointment during the mobiletype study period (2 - 4 weeks).
D: Inclusion Criteria:

* Diagnosis of Bipolar disorder
* Hamilton Depression Scale under or equal to 17
* Young Mania Rating Scale under or equal to 17

Exclusion Criteria:

* Significant somatic disease
* Other severe mental illness (schizophrenia, schizoaffective disorder)
* Lack of technical skills
* Lack of knowledge of Danish
* Pregnancy
* Lack of desire/willingness to use the delivered cell phone as primary phone

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Adjunctive Treatment With Divalproex or Risperidone for Aggression Refractory to Stimulant Monotherapy Among Children With ADHD
Brief Summary: This study will determine the advantages and disadvantages of adding one of two different types of drugs to stimulant treatment for reducing aggressive behavior in children with attention deficit with hyperactivity disorder (ADHD).


Options:
A: Inclusion Criteria:

* Diagnosis of ADHD
* Diagnosis of opposition defiant disorder or conduct disorder
* Score that exceeds the study threshhold on the standardized scale of aggressive behavior

Exclusion Criteria:

* Current psychosis
* Current major depression
* Current pervasive developmental disorder
* Current obsessive compulsive disorder
* Any other anxiety disorder as primary diagnosis
* Mental retardation
B: Inclusion Criteria:

* Presence of ADHD
* Presence of persistent, clinically significant aggression
* Presence of ODD or CD

Exclusion Criteria:

* Presence of psychosis
* Presence of a major developmental disability
* Presence of a major mood disorder
* Contraindications to stimulant, valproate, or risperidone treatment
C: Inclusion Criteria:

* Age: 8-17
* BD type I or II comorbid with ADHD
* Baseline score in the YMRS \> or = 20

Exclusion Criteria:

* IQ \< 70
* Pharmacologic treatment in the last month
* Pregnancy or absence of a contraceptive method in fertile girls
* Diagnoses: pervasive development disorder, schizophrenia, drug abuse or dependency
* Risk of suicide or homicide
* Clinical condition that might interfere in the study
* Known sensibility to aripiprazole
D: Inclusion Criteria:

* Meets current Diagnostic and Statistical Manual for Mental Disorders-Fourth Edition (DSM-IV) diagnostic criteria for AD and demonstrates serious behavioral problems. Diagnosis confirmed by Autism Diagnostic Interview- Revised (ADI-R)
* CGI score \> = 4 AND and Aberrant Behavior Checklist (ABC) Irritability/Agitation subscale score \> = 18 at screening and baseline (randomization)
* Mental age of at least 18 months
* Male or female 6 to 17 years of age, inclusive, at the time of randomization

Exclusion Criteria:

* Patients considered treatment resistant to neuroleptic medication based on lack of therapeutic response to 2 different neuroleptics after treatment of at least 3 weeks each.
* Patients previously treated and not responding to aripiprazole treatment
* The patient is currently diagnosed with another disorder on the autism spectrum, including PDD-NOS, Asperger's Disorder, Rett's Disorder, Fragile-X Syndrome or Childhood Disintegrative Disorder
* Current diagnosis of bipolar disorder, psychosis, or schizophrenia, or major depression
* A seizure in the past year
* History of severe head trauma or stroke
* Patients undergoing non-pharmacologic therapies (e.g., psychotherapy, behavioral modification) must have started at least 2 months prior to the initial screening visit and must remain in a consistent treatment program for the duration of the study.

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Multi-Centre Randomised Controlled Trial of the Effectiveness of Metformin and Clomiphene Citrate for Treating Anovulatory Infertility in Women With Polycystic Ovary Syndrome
Brief Summary: 1. Metformin increases the pregnancy rate when added to the standard treatment of anovulatory polycystic ovary syndrome (PCOS).
2. Metformin in combination with clomiphene, is more effective than clomiphene alone or metformin alone improves fertility outcomes in women with PCOS of reasonably healthy body weight (BMI \</= 32).
3. Metformin improves fertility outcomes in women with BMI \> 32 with PCOS.


Options:
A: Inclusion Criteria

* Eight or fewer menstrual cycles in the past year or intermenstrual periods of 45 days or longer
* Elevated testosterone level
* Good general health
* Sperm concentration in partner of 20 million/ml or greater
* Ability to have intercourse 2-3 times per week
* One functional fallopian tube and normal uterine cavity
B: Inclusion Criteria:

* PCOS
* Prognosis for poor response
* Infertility

Exclusion Criteria:

* Male factor infertility
* Tubal infertility
C: Inclusion Criteria:

* Spontaneous intermenstrual periods of greater than or equal to 45 days or a total of 8 or less periods per year
* Elevated testosterone levels
* General good health
* Off of current medications which may confound response to study medications

Exclusion Criteria:

* Pregnancy
* Lactose Intolerance
* Medical Contraindications
* Elevated Prolactin, 17hydroxyprogesterone, or Follicle stimulating hormone blood tests
* Diabetes, liver, heart, kidney or uncorrected thyroid disease
D: Inclusion Criteria:

* Women between the age of 18 and 39 years inclusive.
* Anovulatory infertility of duration at least 12 months.
* Polycystic ovary syndrome, based on Rotterdam consensus criteria.
* Normal serum prolactin, thyroid function and 17-hydroxyprogesterone.
* Normal serum prolactin, thyroid function and 17-hydroxyprogesterone;

Exclusion Criteria:

* Presence of any other significant infertility factor including male factor, known tubal disease or history of an ectopic pregnancy, known endometriosis affecting the fallopian tubes or ovaries.
* Already taking oral hypoglycaemics.
* Diabetics receiving treatment.
* Renal impairment
* Chronic hepatic disease
* Cardiac Disease
* Alcohol dependency
* Pre-disposition to lactic acidosis
* Previous ovarian drilling procedure, gonadotrophin injection therapy, IUI (intrauterine insemination) or IVF ( in vitro fertilisation).
* For those women who have had previous fertility treatment, the following would be excluded:

  * Women who have had \> 5 cycles of clomiphene citrate
  * Women who have had \> 5 months metformin treatment previously
  * Women who have proven to be resistant to 100mg or more of clomiphene citrate.

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Does Endometrial Injury in the Non-Transfer Cycle Improve the IVF-ET Outcome in the Subsequent Cycle in Patients With Previous Failed IVF Cycles: A Randomized Control Trial
Brief Summary: Implantation of the human embryo is the limiting factor in the success of invitro-fertilization and embryo transfer(IVF-ET).We wanted to find out whether creating a local injury to the endometrium in the non-transfer cycle would improve the IVF-ET outcome in the subsequent cycle.We believe that the injury created causes release of substances which help in implantation.


Options:
A: Inclusion Criteria:

* 18- 38 years old
* at least one patent tube
* unexplained infertility, anovulation, mild to moderate male factor infertility
* previous failed IUI

Exclusion Criteria:

* indicated for ICSI
B: Inclusion Criteria:

* Women ages 18 and over who present to the Oregon Health and Science University Center for Women's Health and the Portland Veteran's Affairs Medical Center with an indication for endometrial biopsy, are literate in English or Spanish, who are willing to participate in the study.

Exclusion Criteria:

* Pregnancy, known or suspected
* Known cervical stenosis
* History of Mullerian tract anomalies
* History of uterine or cervical surgery
* Pelvic inflammatory disease (current or within the past 3 months)
* Sexually transmitted diseases (current)
* Puerperal or post abortion sepsis (current or within the past 3 months)
* Purulent cervicitis (current)
* Known clotting disorder
* Known uterine anomalies or fibroids distorting the cavity in a way incompatible with office endometrial biopsy
* Allergy to any component of the Pipelle or Explora curette
* Patients who are premedicated with analgesics or misoprostol
* Patients who require mechanical cervical dilation or receive paracervical block
C: Inclusion Criteria:

* women with recurrent implantation failure which was defined as 2-6 cycles unsuccessful of IVF-ET in which more than 10 high grade embryo were transferred

Exclusion Criteria:

* age over than 40 years old
* poor responders to ovarian stimulation
D: Inclusion Criteria:

* Previous failed In-vitro fertilization embryo transfer cycle
* Patients who are good responders and have good quality embryos in the previous attempts
* Age of patients upto 37yrs

Exclusion Criteria:

* Those detected to have endometrial tuberculosis in the past, including those treated with Antituberculosis treatment
* Those with intramural fibroid distorting the endometrial cavity/sub-mucous myoma
* Those with sonographically detected hydrosalpinx

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Does Endometrial Injury in the Non-Transfer Cycle Improve the IVF-ET Outcome in the Subsequent Cycle in Patients With Previous Failed IVF Cycles: A Randomized Control Trial
Brief Summary: Implantation of the human embryo is the limiting factor in the success of invitro-fertilization and embryo transfer(IVF-ET).We wanted to find out whether creating a local injury to the endometrium in the non-transfer cycle would improve the IVF-ET outcome in the subsequent cycle.We believe that the injury created causes release of substances which help in implantation.


Options:
A: Inclusion Criteria:

* Infertile women applied to assisted reproduction clinic
* Follicle stimulating hormone \< 12
* Body mass index \< 25
* Patients whom antagonist protocol will be used
* Patients whom at least 2 good-quality embryos obtained
* Patients who are volunteer

Exclusion Criteria:

* Severe male factor (Sperm concentration \<5 M/ml, progressive sperm motility \<%10)
* Uterine anomaly
* Hydrosalphynx
* Difficult embryo transfer
* Patients who previously had a diagnosis of endometriosis and / or adenomyosis
* Endocrine problems (hypothyroidism, hyperthyroidism, hyperprolactinemia, premature ovarian insufficiency)
* Having more than 3 in vitro fertilization failure
* Refusing to participate
B: Inclusion Criteria:

* Previous failed In-vitro fertilization embryo transfer cycle
* Patients who are good responders and have good quality embryos in the previous attempts
* Age of patients upto 37yrs

Exclusion Criteria:

* Those detected to have endometrial tuberculosis in the past, including those treated with Antituberculosis treatment
* Those with intramural fibroid distorting the endometrial cavity/sub-mucous myoma
* Those with sonographically detected hydrosalpinx
C: Inclusion Criteria:

* Women with history of primary or secondary infertility undergoing fresh IVF/ ICSI treatment or frozen embryo replacement cycle
* Age \<49

Exclusion Criteria:

* Non- ovulatory cycles
* Absent uterus
* Uterine instrumentation within previous 3 menstrual cycles
* Women in the oocyte donation program
D: Inclusion Criteria:

* Age \< 43 years
* Normal uterine cavity shown on ultrasound scanning

Exclusion Criteria:

* Age \>=43
* Three previous IVF cycles
* Use of donor oocytes
* Natural IVF or IVM cycles
* Abnormal uterine cavity on ultrasound scanning
* ET canceled because of absent fertilization or risk of ovarian hyperstimulation syndrome
* Blastocyst transfer
* Undergoing preimplantation genetic diagnosis
* Recruited in the same study before

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: QUIT-PRIMO: Web-Delivered Clinical Microsystem Intervention for Tobacco Control
Brief Summary: This is a randomized control trial to determine the efficacy of a multi-modal intervention in improving smoking cessation processes of care and patient outcomes in community-based primary care practices. Our Overall Goal is to advance science related to the use and impact of the Internet in health services delivery, specifically smoking cessation, by targeting primary care clinical microsystems. A clinical microsystem is defined as the smallest functional healthcare unit. A clinical microsystem is not simply equivalent to a clinical team of doctors and nurses, but also the panel of patients cared for by the providers and the processes of care that are used.


Options:
A: Inclusion Criteria:

* Adult (18 years old or above)
* must have email
* logging on to our stop smoking Internet site
* providing consent to enter stop smoking study

Exclusion Criteria:

* Younger than 18 years old
B: Inclusion Criteria:

* ages 18-25 years old
* english literate
* have access to Smartphone or computer with camera
* indicate they go on Facebook "most" (≥ 4) days per week
* have smoked ≥100 cigarettes in their lives and currently smoke at least 1 cigarette per day on 3 or more days of the week

Exclusion Criteria:

* do not read English
* younger than 18 or older than 25 years of age
* do not have access to a Smartphone or computer with a camera
* only go on Facebook 3 or fewer days a week
* have smoked less than 100 cigarettes in their lifetime or do not currently smoke at least 1 cigarette per day on 3 or more days of the week
C: DISEASE CHARACTERISTICS:

* Currently smokes \> 1 cigarette daily by self reporting
* Planning to quit smoking in the next 90 days by self reporting
* Must be a federal employee or federally employed

PATIENT CHARACTERISTICS:

Performance status

* Not specified

Life expectancy

* Not specified

Hematopoietic

* Not specified

Hepatic

* Not specified

Renal

* Not specified

PRIOR CONCURRENT THERAPY: Any prior or concurrent therapy allowed
D: Inclusion Criteria:

* Community based primary care practices who have:

  * Internet access in office
  * Sees 4 - 5 smokers per week

Exclusion Criteria:

* Practices with more than five providers

Answer: D